Rhythm Biosciences’ antibodies pass latest round of tests
Rhythm Biosciences (ASX:RHY), developer of the ColoSTATTM blood test targeting the accurate and early detection of colorectal cancer, has completed the first phase of development of two new antibody reagents.
Four independent mixed monoclonal antibody preparations have now been identified that pass all three preliminary screening tests. This work was completed under RHY’s research contract with CSIRO on time and on budget.
The results of Phase 1 will now trigger the next phase of key reagent development, which involves the cloning of cells that produce the “desired antibody specificities”— separating them from other cells producing other products.
This next cloning step is crucial to ensuring that RHY has a reliable, long-term source of these key reagents, and establishes monoclonal antibody-producing cell lines. Following that, the cell lines will undergo “detailed characterisation, expansion and biobanking”.
Monoclonal antibodies produced by the cell lines will be characterised in detail, in order to identify which is likely to be most suitable for use in RHY’s ColoSTATTM. The company expects the cloning steps to be completed by late June 2018, following which will be the antibody production phase.
As always, it should be noted that RHY is an early stage play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.
More about ColoSTATTM
RHY’s ColoSTATTM uses antibodies to measure the levels of several particular proteins in the blood, which have been shown to vary in the presence of absence of colorectal cancer. The concentration values are then combined using a proprietary algorithm, and this process provides an indication of cancer risk. A returned result above a certain threshold will be an indicator that a patient should progress to a colonoscopy for further investigation.
RHY Managing Director Dr Trevor Lockett commented on today’s news: “Rhythm’s key focus for the coming months is to secure our own antibodies and target proteins to give us control of the supply, quality and cost of these key reagents.
“Confirmation that we have antibodies that pass all three pre-screening tests in four of our mixed antibody populations is excellent news for our product development program. We expect to know if this next, all important cloning process has been successful by late June 2018.”
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.